ArticleBMC chemistry2025
Qualitative and quantitative assessment of related substances for ketoconazole cream based on national drug sampling inspection in China.
Article in BMC chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundEstablishing an analytical method for the detection of related substances in ketoconazole cream is essential for improving product quality standards and ensuring the safety of this formulation.
methodsIn the 2024 National Drug Sampling Specification, we developed a novel high-sensitivity high-performance liquid chromatography (HPLC) method that effectively separates six known impurities, four preservatives, and one antioxidant present in ketoconazole creams. These creams were sourced from random market sampling and exhibited variations in prescription composition across 14 different manufacturers. Subsequently, we conducted the extraction, isolation, and characterization of common unknown impurities from these creams using mass spectrometry (MS), nuclear magnetic resonance spectroscopy (NMR), and infrared (IR) techniques. Furthermore, the structural analysis of unknown impurities within a specific enterprise was performed using high-resolution mass spectrometry and specialized software.
resultsThe established method has been thoroughly validated, demonstrating its specificity, accuracy, sensitivity, and excellent repeatability, thereby confirming its suitability for determining related substances in ketoconazole creams from various manufacturers. This method allowed for both quantitative and qualitative evaluations of impurity content across different manufacturers, identifying sulfonated impurities in ketoconazole creams for the first time and analyzing their formation mechanisms. Furthermore, strategies to reduce these impurities were proposed through correlation analysis and process validation. Additionally, this study innovatively introduced a solvent smoothing agent to mitigate solvent effects, thereby preventing the degradation of the active pharmaceutical ingredient (API) during the heating and dissolution process of the cream matrix. This technique is applicable to the pretreatment of various cream-related substance determinations.
conclusionsThis method provides substantial reference value for establishing analytical methods for related substances in Ketoconazole cream and offers technical support for regulatory agencies in evaluating the quality of Ketoconazole cream.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.